Last updated on December 2019

A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

Brief description of study

A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH on liver biopsy and prevents progression to cirrhosis and/or advanced liver disease

Clinical Study Identifier: NCT03900429

Find a site near you

Start Over

Austin Health

Heidelberg, Australia
  Connect »

The Royal Melbourne Hospital

Parkville, Australia
  Connect »